Lp(a) Is a Major Cardiovascular Risk Factor With Treatments Finally on the Horizon
A comprehensive review reveals why elevated Lp(a) demands universal screening and previews a new wave of targeted therapies entering late-stage trials.
Summary
Lipoprotein(a), or Lp(a), is a genetically determined cardiovascular risk factor linked to atherosclerotic heart disease and aortic stenosis. It affects a substantial portion of the global population, prompting major cardiovascular societies to recommend at least one lifetime screening test for all adults. Until now, no approved drugs have specifically targeted Lp(a) levels. This review from McGill University researchers covers Lp(a) biology, genetics, and its connections to various cardiovascular conditions. Crucially, it highlights a pipeline of novel Lp(a)-lowering therapies — including RNA-based agents — now in late-phase clinical trials. If these trials succeed, clinicians may soon have targeted tools to address an undertreated, common, and heritable cardiovascular risk factor that standard lipid-lowering therapies largely fail to reduce.
Detailed Summary
Elevated lipoprotein(a) — commonly written as Lp(a) — has long been recognized as a cardiovascular risk factor, yet it has historically received far less clinical attention than LDL cholesterol. This comprehensive review from researchers at McGill University and the Montreal Clinical Research Institute aims to correct that gap by synthesizing current knowledge on Lp(a)'s biology, genetics, clinical significance, and emerging treatments.
Lp(a) is unique among cardiovascular risk factors because its plasma levels are largely genetically determined, governed primarily by the LPA gene. This means lifestyle changes and conventional lipid-lowering therapies like statins have minimal impact on Lp(a) concentrations. Elevated Lp(a) is also remarkably common — estimates suggest roughly 20% of the global population carries levels high enough to confer increased cardiovascular risk — making it a public health issue of significant scale.
The review maps Lp(a) to specific cardiovascular phenotypes, including atherosclerotic cardiovascular disease (ASCVD) and calcific aortic valve stenosis, a condition with very few modifiable risk factors. This dual disease association makes Lp(a) a particularly important target. Major cardiovascular societies now recommend at least one Lp(a) measurement in every adult's lifetime to identify high-risk individuals who may benefit from intensified risk management.
Perhaps most exciting is the emerging therapeutic landscape. Several novel agents — including antisense oligonucleotides (such as pelacarsen) and small interfering RNA therapies (such as olpasiran and zerlasiran) — are now in late-phase clinical trials specifically designed to assess whether lowering Lp(a) reduces cardiovascular events. This represents the first real opportunity to test the causal hypothesis and potentially offer targeted treatment.
As a review article, this paper synthesizes existing evidence rather than presenting new trial data. Definitive proof that Lp(a) lowering reduces clinical events awaits trial readouts expected in coming years. Nonetheless, this review provides an authoritative clinical framework for understanding and managing elevated Lp(a) today.
Key Findings
- Lp(a) levels are primarily genetically determined and largely unaffected by statins or lifestyle changes.
- Elevated Lp(a) is linked to both atherosclerotic cardiovascular disease and calcific aortic stenosis.
- Approximately 20% of the global population has cardiovascular risk-elevating Lp(a) levels.
- Major cardiovascular societies now recommend universal one-time Lp(a) screening for all adults.
- Novel RNA-based therapies targeting Lp(a) are currently in late-phase clinical trials and show strong lowering potential.
Methodology
This is a comprehensive narrative clinical review article, not a primary research study or meta-analysis. The authors synthesize published literature on Lp(a) biology, genetics, clinical associations, and drug development. No new experimental data or patient cohorts were analyzed.
Study Limitations
This is a review article and therefore subject to the authors' selection of literature, which may not capture all relevant evidence. No new clinical data are presented, and the clinical benefit of Lp(a)-lowering therapies remains unproven pending ongoing trial results. The abstract alone was available, so specific details about evidence thresholds and therapy comparisons could not be fully assessed.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.